WG Partners
WG Partners is a London-based, FCA-regulated specialist life sciences boutique investment bank, 100% partner-owned, providing corporate advisory, M&A and capital raising services to public and private healthcare and technology companies across the UK, Australia and broader international markets.
- Company typePrivate
- Founded2015
- HeadquartersLondon, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
What WG Partners does
WG Partners is a specialist life sciences boutique investment bank providing corporate advisory, mergers and acquisitions, and capital raising services to public and private healthcare and technology companies. The firm is structured as WG Partners LLP in the United Kingdom, authorised and regulated by the Financial Conduct Authority (FRN:595861), with an Australian operating subsidiary, WG Partners Pty Ltd., based in Sydney. Headquartered at 85 Gresham Street in London, the firm is 100% owned by its working partners, who collectively bring more than 250 years of relevant City experience spanning investment banking, equity research, corporate broking and institutional sales with a life sciences specialism. The partners' biographies show backgrounds at Piper Jaffray, ING Barings, Deutsche Bank, UBS, ABN AMRO, Merrill Lynch, Singer Capital Markets, Hawkpoint Partners and HSBC, supplemented by scientific credentials including PhDs in Pharmacology and Physiology and an MSc in Biotechnology from Imperial College London. This combination of senior banker pedigree and scientific training underpins the firm's positioning as a sector specialist.
The firm's commercial proposition centres on discreet, conflict-free advisory delivery given the partner-only ownership structure. Across its operating history it reports 175 fundraisings and 47 M&A transactions since 2005 (a second source scope extends transaction value to "more than £8.4 billion" completed over the last decade), with over 60% of M&A deals conducted cross-border, indicating that international issuer and institutional investor coverage is a core capability rather than an aspiration. Customer segments are concentrated in life sciences — biotechnology, pharmaceuticals, medical devices, diagnostics, gene therapy and adjacent healthcare technology — across both public companies (fundraises, secondary offerings, IPO advisory) and private companies (growth capital, M&A, strategic transactions), with approximately 100 corporate clients served since foundation. The marketing and distribution model is relationship-led and field-sales-driven, with the wgpartners.co.uk website as the primary public channel and no digital marketing or productised technology offerings.
The underlying technology footprint is minimal by design: WG Partners is explicitly a professional services firm rather than a software or AI platform, with no API, SDK, integrations, mobile apps or proprietary technology products disclosed. Revenue mechanics follow a standard boutique investment banking model — advisory retainers, M&A transaction fees, and capital raising success fees — with pricing not publicly disclosed and tailored per mandate. Recent strategic emphasis has been on deepening AI-enabled healthcare and diagnostics coverage (via Partner Parthiv Patel's prior roles at Owkin AI and nference) and on adding analytical bench strength (Alice Whelan, Imperial-trained biotechnologist), alongside continued cross-border mandate execution in both the UK and Australia.
WG Partners firmographics
Firmographics- Name
- WG Partners
- Legal name
- WG Partners LLP
- Website
- https://wgpartners.co.uk
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- WG Partners is a London-based, FCA-regulated specialist life sciences boutique investment bank, 100% partner-owned, providing corporate advisory, M&A and capital raising services to public and private healthcare and technology companies across the UK, Australia and broader international markets.
- Ownership category
- akta.pro rank
WG Partners industry classification
Industry- Product category
- Life Sciences Investment Banking
- NAICS
- Securities and Commodity Contracts Intermediation and Brokerage (5231)
- SIC
- Security Brokers, Dealers & Flotation Companies (6211)
- akta.pro primary industry
- Industry-Specialist / Sector-Focused M&A Advisory (FSAEAGAJ)
- akta.pro secondary industry
- Corporate Development & Strategic Partnerships Advisory (JVs, Alliances, Carve-outs) (BPAHAOAG)
Keywords
Where WG Partners is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
WG Partners business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Corporate Advisory Services: Provides corporate advisory services to life sciences companies including strategic advice, M&A transaction execution, and capital raising advisory.
- M&A Transaction Fees: Earns fees from advising on M&A transactions including IPOs, acquisitions, and disposals for life sciences companies.
- Capital Raising Services: Provides capital raising advisory including fundraises, secondary offerings, and private placements for life sciences companies.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels1 record
WG Partners product offering
Product offeringCore offering
WG Partners is a specialist life sciences boutique that provides corporate advisory, mergers and acquisitions (M&A), and capital raising services to public and private companies in the biotech, pharma, med-tech, and diagnostics sectors. The firm acts as financial advisor and strategic advisor on transactions, supported by senior partners with deep sector experience and direct access to international institutional investors.
Product overview
WG Partners is a specialist life sciences boutique providing corporate advisory, M&A (mergers and acquisitions), and capital raising services. The firm operates as a unified advisory service rather than a product-based platform, with no distinct software products, modules, or technology offerings. Services are delivered directly by partners with over 250 years of combined experience, serving corporate and institutional clients across transactions valued in excess of £8.4 billion. The company has offices in London and Sydney and is authorized and regulated by the Financial Conduct Authority (FRN:595861).
Differentiator
Problem solved
Functional benefit
Products and services
- Corporate Advisory Discreet, proactive, and objective corporate advisory provided to public and private life sciences companies. Covers strategic advice on corporate transactions, shareholder matters, and long-term positioning, delivered by senior partners with deep life sciences expertise.
- M&A Advisory Financial advisory on mergers and acquisitions for life sciences corporates, including IPOs, acquisitions, and disposals. Over 60% of M&A transactions are cross-border, drawing on the firm's London and Sydney presence and international investor network.
- Capital Raising Advisory and execution support for capital raises by life sciences companies, including fundraisings, secondary offerings, private placements, and convertible loans, leveraging unique access to the international institutional investor community.
Quantifiable outcome
- Completed transactions with total value in excess of £8.4 billion
- +3 more outcomes
Companies that use WG Partners
Customer profileNamed customers45 records
Segments3 records
Ideal customer profiles1 record
WG Partners technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
WG Partners partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Sansure BiotechminorSansure Biotech partnered with WG Partners client QuantuMDx in a cooperation agreement in September 2022. This partnership was facilitated as part of WG Partners' advisory relationship with QuantuMDx.
Scale indicators6 records
Recent moves5 records
Expansion highlights4 records
WG Partners competitors and assessment
Company assessmentDirect peers
- Bryan, Garnier & Co: European sector specialist investment bank with deep healthcare and life sciences M&A and capital raising capabilities. Closest peer to WG Partners in terms of boutique scale and sector specialization, serving European growth companies in healthcare, tech, and energy.
- H.C. Wainwright & Co. US-based healthcare specialist investment bank focused on biotech, medtech, and life sciences M&A, capital raises, and equity research. Closely comparable to WG Partners in its pure-play healthcare focus and small-cap biotech deal expertise.
- goetzpartners: German-headquartered independent advisory firm with a dedicated healthcare and life sciences practice, providing M&A and corporate finance services to European life sciences companies. Comparable scale and sector focus to WG Partners.
- Northridge Advisory: UK-based independent advisory firm specializing in healthcare and life sciences M&A. Directly comparable to WG Partners in scale and sector focus; Robin Sturken (current WG Partners partner) was previously at Northridge for eight years.
Broad incumbents
- Jefferies: Major global investment bank with one of the largest dedicated healthcare M&A teams. Competes with WG Partners for life sciences mandates but offers a full-service platform including sales, trading, research, and balance sheet financing alongside advisory.
- Canaccord Genuity: Global capital markets firm with a strong healthcare and life sciences M&A and equity capital markets franchise. Competes for biotech mandates at a larger scale with broader geographic reach than WG Partners.
- Piper Sandler: US-based investment bank with a leading healthcare group (formerly Piper Jaffray, where WG Partners' chairman David Wilson was previously CEO). Comparable sector expertise but operating at much larger scale.
- Stifel Financial: Global investment bank with a dedicated healthcare group serving biotech, pharma, and medtech clients. Competes for healthcare M&A and capital raising mandates at a larger scale than WG Partners.
Regional players
- finnCap: UK-based smaller companies investment bank and advisory firm (now part of Cavendish). Overlaps with WG Partners in advising UK smaller-cap life sciences companies on capital raising and M&A, though with broader sector coverage.
- Peel Hunt: UK mid-market investment bank with healthcare coverage. Competes with WG Partners for UK life sciences mandates but operates as a generalist mid-market adviser rather than a sector specialist.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
WG Partners social profiles
Digital presenceWG Partners financial estimates
Financial estimateRevenue estimate
Valuation estimate
WG Partners leadership team
Management profileNumber of profiles
Profiles10 records
WG Partners subsidiaries and ownership
Company hierarchySubsidiaries1 record
WG Partners funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
WG Partners M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about WG Partners
What does WG Partners do?
WG Partners is a specialist life sciences boutique that provides corporate advisory, mergers and acquisitions (M&A), and capital raising services to public and private companies in the biotech, pharma, med-tech, and diagnostics sectors. The firm acts as financial advisor and strategic advisor on transactions, supported by senior partners with deep sector experience and direct access to international institutional investors.
Is WG Partners a public or private company?
WG Partners is a private company. It is classified as management employee owned and is currently operating.
When was WG Partners founded?
WG Partners was founded in 2015. It employs 1 to 10 people.
Where is WG Partners based?
WG Partners is headquartered in London, United Kingdom, in the Europe region.
How does WG Partners make money?
Three revenue lines are on record. Corporate Advisory Services are the primary driver. The others are M&A Transaction Fees and capital Raising Services.
Who are WG Partners's main competitors?
Direct peers on record are Bryan, Garnier & Co, H.C. Wainwright & Co., goetzpartners and Northridge Advisory. Broad incumbents are Jefferies, Canaccord Genuity, Piper Sandler and Stifel Financial. Regional players are finnCap and Peel Hunt.
Does WG Partners have an API?
No public API is recorded for WG Partners.
What industry is WG Partners in?
WG Partners's product category is Life Sciences Investment Banking. Its primary akta.pro industry code is FSAEAGAJ, Industry-Specialist / Sector-Focused M&A Advisory, with a secondary code of BPAHAOAG, Corporate Development & Strategic Partnerships Advisory (JVs, Alliances, Carve-outs). Its NAICS code is 5231 and its SIC code is 6211.